Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis
Key facts
- Who runs it
- Cedars-Sinai Medical Center
- Where
- Columbus, Los Angeles, Pittsburgh, and Stanford, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 90 people, planned
- Started
- 24 Oct 2024
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Simvastatin
- Placebo
- Record updated
- 5 August 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18-75 at time of enrollment
- Diagnosis of Recurrent Acute or Chronic Pancreatitis not attributable to gallstones (i.e., suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis. For CP, imaging studies that can be used for diagnosis classification using Cambridge criteria46,47
- Ability to take oral medication and be willing to adhere to the dosing regimen
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication
- No prior pancreatic surgery
- No current statin use for 6 months
Who cannot take part
- History of autoimmune, medication caused or traumatic pancreatitis
- Pancreatic metastasis from other malignancies
- History of solid organ transplant, HIV/AIDS
- Known isolated pancreatic exocrine insufficiency (i.e.., in the absence of any eligible inclusion criteria)
- Subjects required to take itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, or verapamil for other clinical indications
- Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up
- Patients with active liver disease
- Known Pregnancy. All participants of childbearing potential, except if post-menopausal (i.e., no menses for ≥2 years) or had a hysterectomy, bilateral tubal ligation/clip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test
- Pregnancy or lactation
- Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (>1 cm. in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors
- Current simvastatin use within the past 6 months
- Currently incarcerated
- Inability to comply with study activities
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Recurrent acute pancreatitis or chronic pancreatitis
This trial is currently available in United States.
- Ohio State UniversityColumbus, United StatesContact: Spencer HarrisTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Arax ShanlianTaking people
- University of Southern CaliforniaLos Angeles, United StatesContact: Jorge Zuniga-GomezTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Kelly WoodTaking people
- Stanford UniversityStanford, United StatesContact: Lorena PinedaTaking people
About the trial
What the trial wants to find out
The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).
The 2 groups in the trial
- SimvastatinTreatment being tested
Participants receive Simvastatin 40mg capsule once daily for 6 months.
- PlaceboPlacebo, for comparison
Participants receive Placebo capsule matching Simvastatin once daily for 6 months.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT05771675, who can take part
- Record updated
- 5 August 2026